Press Releases August 28, 2026 08:00 AM

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Minerva Neurosciences Announces Participation in September 2026 Investor Conferences

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
NERV

Minerva Neurosciences, a clinical-stage biopharmaceutical company focused on CNS disorders, announced that its management will participate in two upcoming investor conferences in New York, including the Wells Fargo Healthcare Conference and the 2026 Cantor Global Healthcare Conference. The company will webcast its presentations and provide replay access on its website.

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
NERV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Minerva Neurosciences is actively engaging with investors through participation in major healthcare conferences in September 2026.
  • Company's ongoing focus is on developing therapies for central nervous system diseases, notably a Phase 3 trial of roluperidone for schizophrenia negative symptoms.
  • Webcast and replay availability increase accessibility for broader investor audience.

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.

Wells Fargo Healthcare Conference
Date: Tuesday, September 8
Format: 1x1 meetings
Location: New York, NY

2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9
Format: Fireside chat and 1x1 meetings
Time: 2:45 – 3:15 PM EDT
Location: New York, NY                                                                                                                                                                                           

If you are interested in meeting with the Minerva team during the conferences, please reach out to your respective conference representative.

The live webcast can be accessed in the events section of the Minerva Neurosciences website HERE. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.

Contacts:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
[email protected]

Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
[email protected]


Risks

  • The company is in clinical-stage development, which carries inherent risks related to trial outcomes affecting future approvals and market acceptance.
  • Investor engagement via conferences does not guarantee positive clinical or financial results, so market impact may be limited.
  • Dependence on progress in the CNS therapeutic sector and regulatory environment may introduce uncertainties.

More from Press Releases

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs Aug 28, 2026 New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients Aug 28, 2026 Nano Labs Announces First Half of 2026 Financial Results Aug 28, 2026 Rezolve Ai and Tech Mahindra Forge Global Alliance to Bring Agentic Commerce to Enterprise Scale Aug 28, 2026 ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split Aug 28, 2026